iosBio
2 known investors
iosBio develops oral, thermostable vaccine candidates using its ESD platform, with a lead program (OraPro-EBV) targeting Epstein-Barr Virus. The company operates in the biotechnology and vaccine development sector.
Founders & leadership
WC
Wayne ChannonExecutive Chairman
EB
Elliot BlandCOO
CL
Craig LaferrièreCDO
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- IOSBIO LTD
- Company number
- 04497290
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 29 Jul 2002
- Registered office
- Hayworthe House, Market Place, Haywards Heath, RH16 1DB
- Nature of business (SIC)
- 86900 — Other human health activities
- Previous names
- STABILITECH BIOPHARMA LTD (2016–2020)STABILITECH LTD (2002–2016)
- Accounts
- last made up to 31 Jul 2025 · next due 30 Apr 2027
- Confirmation statement
- last made up to 5 Nov 2025 · next due 19 Nov 2026
Current officers · 6
- Colin Neil Maltby — secretary, appointed 26 Aug 2020
- Elliot Bland — director, appointed 16 Jan 2018
- Wayne Matthew Channon — director, appointed 26 Mar 2007
- Peter John Cozens — director, appointed 5 Feb 2009
- Craig Antony Joseph Laferriere — director, appointed 16 Jul 2024
- Myra Nicole Waiman — director, appointed 6 Jan 2015
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does iosBio do?
- iosBio develops oral, thermostable vaccine candidates using its ESD platform, with a lead program (OraPro-EBV) targeting Epstein-Barr Virus. The company operates in the biotechnology and vaccine development sector.
- Who are iosBio's investors?
- iosBio's investors include Innvotec Ltd., Shackleton Ventures Ltd..